Pacific Biosciences, a provider of high-quality, long-read sequencing platforms, completed the acquisition of Omniome, a San Diego-based company developing a highly differentiated, proprietary short-read sequencing platform capable of delivering high accuracy, for $800m. "The team at Omniome has spent several years developing a new and differentiated sequencing chemistry, Sequencing by Binding. We developed this chemistry because clinical applications require a level of accuracy that is difficult to achieve with current sequencing technologies. SBB has fundamental advantages over other technologies and the potential to deliver higher sensitivity at a lower cost to unlock new markets," Richard Shen, Omniome President.